Liana Apostolova
Neurology · Indianapolis, INNPI 1770508699
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,961 of the $95,224 with a category attached, or 86.1%. 12 manufacturers reported payments, led by Eisai Inc. at 31.9% of the total. Reporting peaked in 2023 at $37,770 and has fallen 77.3% since, to $8,565 in 2024. Among neurology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $1670.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$30K
- Eli Lilly$17K
- Biogen$14K
- Roche Diagnostics Corporation$5K
- Alnylam Pharmaceuticals Inc.$5K
- Corium, LLC$5K
- plus $18K from 6 others
Across 7 payments — averaging $127,890 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Corporation$895K
What the payments were for
- Consulting fees$81,96186%
- Speaking & faculty fees$2,5243%
- Travel & lodging$9,92110%
- Food & beverage$7941%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 19 | $30,357 |
| Eli Lilly | 20 | $17,483 |
| Biogen | 4 | $14,221 |
| Roche Diagnostics Corporation | 2 | $5,424 |
| Alnylam Pharmaceuticals Inc. | 3 | $5,150 |
| Corium, LLC | 1 | $4,960 |
| Siemens Medical Solutions USA, Inc. | 1 | $4,800 |
| F. Hoffmann-la Roche AG | 1 | $4,485 |
| Genentech, Inc. | 2 | $2,921 |
| Roche Products Limited | 1 | $2,760 |
| Genentech USA, Inc. | 1 | $2,070 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $593 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$95,224 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 49 | $1,926 |
| Donepezil Hcl | 101 | $864 |
| Quetiapine Fumarate | 23 | $801 |
| Escitalopram Oxalate | 15 | $224 |
| Mirtazapine | 11 | $140 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indianapolis
- Cassandra CurtisIndianapolis$181K
- Martin FarlowIndianapolis$148K
- Eric SiemersIndianapolis$101K
- Jared BroschIndianapolis$68K
- Kaustubh LimayeIndianapolis$44K
- Michael SermersheimIndianapolis$32K
- Cynthia McGarveyIndianapolis$27K
- David GlanderIndianapolis$25K
- Leo DambrosioIndianapolis$25K
- Kuimil MohanIndianapolis$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.